Bio Pharma Dive
DECEMBER 3, 2024
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
Pharmaceutical Technology
DECEMBER 3, 2024
Turkiye’s pharmaceutical industry has grappled with significant economic challenges such as the frequent upward revision of the pharmaceutical Euro exchange rate.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
DECEMBER 3, 2024
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
Pharmaceutical Technology
DECEMBER 3, 2024
Olema Oncology and Novartis have signed a clinical trial collaboration and supply agreement for a Phase III trial in metastatic breast cancer.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
DECEMBER 3, 2024
A change in ownership and what it means for our readers.
Pharmaceutical Technology
DECEMBER 3, 2024
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 3, 2024
J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.
pharmaphorum
DECEMBER 3, 2024
Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position
Pharmaceutical Technology
DECEMBER 3, 2024
Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.
Pharmaceutical Commerce
DECEMBER 3, 2024
The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.
Fierce Pharma
DECEMBER 3, 2024
On the heels of similar deals in the U.S. and the EU, the U.K. is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. | On the heels of similar deals in the U.S. and the European Union, the United Kingdom is filling up its coffers with doses of bird flu immunizations from Australia’s CSL Seqirus. To prepare for a potential future pandemic, the U.K. has inked an accord with CSL Seqirus to acquire more than 5 million doses of the company’s H5 influenza shot.
Intouch Solutions
DECEMBER 3, 2024
EVERSANA INTOUCH recently hosted an insightful panel at the 2024 ProcureCon Marketing conference in Los Angeles. The panel, titled “The Balancing Act: Sourcing & Pricing Meet Innovation in Life Sciences,” brought together industry leaders to discuss the intersection of cost efficiency and innovation in the dynamic field of life sciences.
Drug Patent Watch
DECEMBER 3, 2024
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
pharmaphorum
DECEMBER 3, 2024
Tune in to the podcast interview with Dr Sharmeen Roy to learn more about precision dosing and how DoseMe is providing effective and safe treatment for all through personalised dosing solutions.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
DECEMBER 3, 2024
The process of obtaining a patent for a drug invention can be complex and time-consuming. Despite the best efforts of inventors and patent attorneys, many drug patent applications are rejected by patent offices. Understanding the common reasons for these rejections is crucial for overcoming them and securing patent protection for innovative pharmaceuticals.
Drug Channels
DECEMBER 3, 2024
It’s time to pay attention to the money behind the 340B curtain. Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more. There are important limitations to these data.
pharmaphorum
DECEMBER 3, 2024
Get to know Jackie Marchington, an expert in IPG Health Medical Communications, through this exclusive interview. Learn about her insights, experiences, and perspectives on the industry.
Pharma Times
DECEMBER 3, 2024
Partnership aims to develop new radiopharmaceuticals for cancer treatment
pharmaphorum
DECEMBER 3, 2024
Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy
CTTI (Clinical Trials Transformation Initiative)
DECEMBER 3, 2024
In December 2022, Congress passed the Food and Drug Omnibus Reform Act (FDORA) requiring drug and device manufacturers to develop and submit diversity action plans (DAPs) for Phase III and other pivotal trials outlining how they plan to recruit, enroll, and retain a population that reflects the patient population with the disease or condition in the US that is expected to use the medical product if approved, licensed, authorized, cleared, or classified.
pharmaphorum
DECEMBER 3, 2024
Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
Pharmaceutical Commerce
DECEMBER 3, 2024
The latest news for pharma industry insiders.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
DECEMBER 3, 2024
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements
pharmaphorum
DECEMBER 3, 2024
Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m
Expert insights. Personalized for you.
130 
Let's personalize your content